查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1532244

注射給藥市場：2024-2033年全球產業分析、規模、佔有率、成長、趨勢、預測

Injectable Drug Delivery Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
出版日期: | 出版商: Persistence Market Research | 英文 307 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

Persistence Market Research最近發布了一份關於全球注射給藥市場的綜合報告。本報告全面評估了主要市場動態，包括市場驅動因素、趨勢、機會和挑戰，並提供了有關市場結構的詳細見解。

關鍵見解

  • 注射給藥市場規模（2024年）：491億美元
  • 預測市場規模（2033年）：1,012億美元
  • 全球市場成長率（2024-2033年年複合成長率）：8.4%

注射給藥市場-調查範圍：

注射給藥系統在給藥中發揮重要作用，具有起效快、生物利用度高和劑量精確等優點。這些系統對於廣泛的治療應用非常重要，包括糖尿病管理、腫瘤學、心血管疾病和自體免疫疾病。注射藥物輸送市場面向醫院、診所、家庭健康場所和專業醫療機構，提供各種輸送系統，包括傳統注射器、自動注射器、筆式注射器和無針注射器。

推動市場成長的因素：

全球注射給藥市場由幾個關鍵因素推動，包括需要頻繁給藥的慢性疾病（如糖尿病和癌症）盛行率的上升。注射給藥系統的技術進步，例如智慧注射器和連網注射器的開發，將提高患者的依從性和治療效果，進一步推動市場成長。此外，對需要注射給藥的生物製劑和生物相似藥的需求不斷成長也促進了市場的擴張。在用戶友善和以患者為中心的注射器的支持下，向自我給藥的轉變也在市場成長中發揮重要作用。

市場限制因素：

儘管成長前景廣闊，但注射給藥市場仍面臨監管合規性、製造複雜性和先進給藥系統高成本等挑戰。有關注射器審批和銷售的嚴格規定給製造商帶來了合規負擔，影響了市場進入障礙和營運成本。此外，對針刺傷害風險以及注射藥物的安全性和有效性的擔憂對市場滲透構成了挑戰。解決這些監管和安全問題需要行業利益相關者、醫療保健提供者和監管機構共同努力，加速採用安全有效的注射給藥解決方案。

市場機會：

由於技術創新、個人化醫療趨勢和擴大醫療保健服務範圍，注射給藥市場提供了巨大的成長機會。數位健康技術的集成，例如具有監控功能的智慧注射器，可以提高患者的用藥依從性，並向醫療保健提供者提供即時資料。此外，對個人化醫療和標靶治療的日益關注為針對個別患者需求量身定制的注射給藥系統開闢了新途徑。策略合作夥伴關係、研發投資以及引進具有成本效益且易於使用的給藥解決方案對於利用新的商機並保持在動態注射劑市場的領先地位非常重要。

本報告涵蓋的主要問題

  • 推動全球注射給藥市場成長的關鍵因素是什麼？
  • 哪些輸送系統和應用推動注射給藥在各種醫療保健環境中的採用？
  • 技術進步如何改變注射給藥市場的競爭格局？
  • 誰是注射給藥市場的主要參與者？
  • 全球注射給藥市場的新趨勢和未來前景如何？

目錄

第1章 執行摘要

第2章 市場概述

  • 市場範圍/分類
  • 市場定義/範圍/限制
  • 包含和排除

第3章 主要市場趨勢

  • 影響市場的主要趨勢
  • 產品創新/發展趨勢

第4章 關鍵成功因素

  • 產品採用率分析
  • 市場進入者的主要策略
  • PESTLE分析
  • 波特的分析
  • 疾病流行病學
  • 主要規定
  • 供應鏈分析
  • 腸外藥物管道評估

第5章 市場背景

  • 宏觀經濟因素
  • 預測因子 - 相關性和影響
  • 市場動態

第6章 COVID-19 危機分析

  • 新冠肺炎（COVID-19）影響分析
    • 依產品
    • 依用途
    • 依適應症
    • 依通路
  • 2024年市場情景

第7章 全球注射給藥市場（數量或規模）分析

  • 2019-2023年市場價值分析
  • 2024-2033年市場價值預測
    • 年成長趨勢分析
    • 絕對的獲利機會

第8章 全球注射給藥市場分析：依產品

  • 簡介/主要發現
  • 2019-2023年市場規模分析（金額）
  • 2024-2033年市場規模分析與預測（金額）
    • 自注射器
    • 無針注射器
    • 自動注射器
    • 穿戴式注射器
    • 胰島素筆
  • 依產品分析市場吸引力

第9章 全球注射給藥市場分析：依技術

  • 簡介/主要發現
  • 2019-2023年市場規模分析（金額）
  • 2024-2033年市場規模分析與預測（金額）
    • 非智慧型注射器
    • 智慧型注射器
      • 人工智慧（AI）與機器學習的集成
      • 近場通訊（NFR）
      • 雲端運算
      • 藍牙
  • 依技術分析市場吸引力

第10章 全球注射給藥市場分析：依應用

  • 簡介/主要發現
  • 2019-2023年市場規模分析（金額）
  • 2024-2033年市場規模分析與預測（金額）
    • 一次性注射器
    • 可重複使用的注射器
  • 依應用分析市場吸引力

第11章 全球藥物傳輸市場分析：依適應症

  • 簡介/主要發現
  • 2019-2023年市場規模分析（金額）
  • 2024-2033年市場規模分析與預測（金額）
    • 過敏反應
    • 糖尿病
    • 心血管疾病
    • 多發性硬化症
    • 類風濕性關節炎
    • 癌症
    • 其他
  • 依症狀分析市場吸引力

第12章 全球注射給藥市場分析：依通路劃分

  • 簡介/主要發現
  • 2019-2023年市場規模分析（金額）
  • 2024-2033年市場規模分析與預測（金額）
    • 醫院藥房
    • 藥局
    • 零售藥局
    • 網路藥局
  • 依通路分析市場吸引力

第13章 全球注射給藥市場分析：依地區

  • 簡介
  • 2019-2023年市場規模分析（金額）
  • 2024-2033年市場規模分析與預測（金額）
    • 北美
    • 拉丁美洲
    • 歐洲
    • 南亞
    • 東亞
    • 大洋洲
    • 中東和非洲
  • 區域市場吸引力分析

第14章 北美注射給藥市場分析

第15章 拉丁美洲注射給藥市場分析

第16章 歐洲注射給藥市場分析

第17章 南亞注射給藥市場分析

第18章 東亞注射給藥市場分析

第19章 大洋洲注射給藥市場分析

第20章 中東及非洲注射給藥市場分析

第21章 市場結構分析

  • 依公司層級的市場分析
  • 主要公司市佔率分析
  • 市場現況分析

第22章 競爭分析

  • 競爭儀表板
  • 競爭詳情
    • Eli Lilly and Company
    • Biocon
    • Becton, Dickinson &Company
    • West Pharmaceutical Services, Inc.
    • Johnson &Johnson
    • Antares Pharma
    • AbbVie Inc
    • Pfizer Inc.
    • Mylan NV
    • Vetter Pharma-Fertigung GmbH &Co.KG
    • Emperra GmbH
    • Digital Medics Pty Ltd
    • Enable Injections LLC
    • Insulet corporation
    • Consort Medical Plc
    • Diabnext
    • Diamesco Co., Ltd
    • SCHOTT AG
    • SiO2 Medical Products
    • Integrity Bio, Inc.
    • Wilhelm Haselmeier GmbH &Co. KG
    • Tandem Diabetes Care
    • Sanofi SA
    • Companion Medical Inc.
    • Ypsomed
    • F.Hoffman-La Roche Ltd.
    • Novo Nordisk A/S
    • Medtronic Plc.

第23章 使用的先決條件與縮寫

第24章 研究方法

簡介目錄
Product Code: PMRREP3774

Persistence Market Research has recently released a comprehensive report on the worldwide market for injectable drug delivery. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Injectable Drug Delivery Market Size (2024E): USD 49.1 Bn
  • Projected Market Value (2033F): USD 101.2 Bn
  • Global Market Growth Rate (CAGR 2024 to 2033): 8.4%

Injectable Drug Delivery Market - Report Scope:

Injectable drug delivery systems play a crucial role in the administration of medications, offering advantages such as rapid onset of action, improved bioavailability, and precise dosage delivery. These systems are essential for a wide range of therapeutic applications, including diabetes management, oncology, cardiovascular diseases, and autoimmune disorders. The injectable drug delivery market caters to hospitals, clinics, home care settings, and specialized healthcare facilities, offering a variety of delivery systems, including conventional syringes, auto-injectors, pen injectors, and needle-free injectors.

Market Growth Drivers:

The global injectable drug delivery market is propelled by several key factors, including the rising prevalence of chronic diseases such as diabetes and cancer, which necessitate frequent drug administration. Technological advancements in injectable drug delivery systems, such as the development of smart and connected injectors, enhance patient compliance and treatment outcomes, further driving market growth. Additionally, the increasing demand for biologics and biosimilars, which require injectable delivery, contributes to market expansion. The shift towards self-administration of drugs, supported by user-friendly and patient-centric injectable devices, also plays a significant role in market growth.

Market Restraints:

Despite promising growth prospects, the injectable drug delivery market faces challenges related to regulatory compliance, manufacturing complexities, and the high cost of advanced delivery systems. Stringent regulations governing the approval and marketing of injectable devices impose compliance burdens on manufacturers, affecting market entry barriers and operational costs. Furthermore, the risk of needlestick injuries and concerns regarding the safety and efficacy of injectable drugs pose challenges for market penetration. Addressing these regulatory and safety concerns requires collaboration between industry stakeholders, healthcare providers, and regulatory agencies to promote the adoption of safe and effective injectable drug delivery solutions.

Market Opportunities:

The injectable drug delivery market presents significant growth opportunities driven by technological innovations, personalized medicine trends, and expanding healthcare access. The integration of digital health technologies, such as smart injectors with monitoring capabilities, enhances patient adherence and provides real-time data for healthcare providers. Furthermore, the increasing focus on personalized medicine and targeted therapies creates new avenues for injectable drug delivery systems tailored to individual patient needs. Strategic partnerships, investment in research and development, and the introduction of cost-effective and user-friendly delivery solutions are essential to capitalize on emerging opportunities and sustain market leadership in the dynamic injectable drug delivery landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the injectable drug delivery market globally?
  • Which delivery systems and applications are driving the adoption of injectable drug delivery across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the injectable drug delivery market?
  • Who are the key players contributing to the injectable drug delivery market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global injectable drug delivery market?

Competitive Intelligence and Business Strategy:

Leading players in the global injectable drug delivery market, including Pfizer Inc., Becton, Dickinson and Company, and Novo Nordisk A/S, focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced delivery systems, including smart injectors, biodegradable implants, and long-acting formulations, catering to diverse patient needs and therapeutic requirements. Collaborations with pharmaceutical companies, healthcare providers, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving injectable drug delivery landscape.

Key Companies Profiled:

  • Eli Lilly and Company
  • Biocon
  • Becton, Dickinson & Company
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan N.V.
  • Vetter Pharma-Fertigung GmbH & Co.KG
  • Emperra GmbH
  • Digital Medics Pty Ltd
  • Enable Injections LLC
  • Insulet corporation
  • Consort Medical Plc.
  • Diabnext
  • Diamesco Co., Ltd

Key Segments Covered in Injectable Drug Delivery Industry Research

Product:

  • Self-Injectors
  • Needle Free Injectors
  • Auto Injectors
  • Wearable Injectors
  • Insulin Pens

Technology:

  • Non-Smart Injectors
  • Smart Injectors

Usage:

  • Disposable Injectors
  • Reusable Injectors

Indication:

  • Anaphylaxis
  • Diabetes
  • Cardiovascular Diseases
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Cancer
  • Trauma and Emergency

Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions & Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Key Strategies, by Market Players
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Analysis
  • 4.5. Disease Epidemiology
  • 4.6. Key Regulations
  • 4.7. Supply Chain Analysis
  • 4.8. Parenteral Drugs Pipeline Assessment

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. GDP Growth Outlook
    • 5.1.2. Healthcare Industry Market Outlook
    • 5.1.3. Global Drug Delivery Industry Overview
    • 5.1.4. R&D Expenditure Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Top Companies Historical Growth
    • 5.2.2. New/Improved Product Launches
    • 5.2.3. Growing Geriatric Population
    • 5.2.4. Prevalence of Diabetes
    • 5.2.5. Technological Advancements
    • 5.2.6. Mergers and Acquistions
    • 5.2.7. Strategic Collaborations
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 Impact Analysis
    • 6.1.1. By Product
    • 6.1.2. By Technology
    • 6.1.3. By Usage
    • 6.1.4. By Indication
    • 6.1.5. By Distribution Channel
  • 6.2. 2024 Market Scenario

7. Global Injectable Drug Delivery Market (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033, by Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Product, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product 2024-2033
    • 8.3.1. Self Injector
      • 8.3.1.1. Single Chamber Self Injector
      • 8.3.1.2. Dual Chamber Self Injector
    • 8.3.2. Needle Free Injectors
      • 8.3.2.1. Pre-Filled Needle Free Injectors
      • 8.3.2.2. Fill-Able Needle Free Injecors
    • 8.3.3. Auto Injectors
      • 8.3.3.1. Pre-Filled Auto Injector
      • 8.3.3.2. Fill-Able Auto Injector
    • 8.3.4. Wearable Injectors
      • 8.3.4.1. Wearable Patch Injectors
      • 8.3.4.2. Off-body Worn Injectors
    • 8.3.5. Insulin Pens
      • 8.3.5.1. Reusable Insulin Pens
      • 8.3.5.2. Disposable Insulin Pens
      • 8.3.5.3. Smart Insulin Pens
  • 8.4. Market Attractiveness Analysis By Product

9. Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033, by Technology

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis By Technology, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Technology, 2024-2033
    • 9.3.1. Non-Smart Injectors
    • 9.3.2. Smart Injectors
      • 9.3.2.1. Artificial Intelligence (AI) & Machine Learning Integrated
      • 9.3.2.2. Near Field Communication(NFR)
      • 9.3.2.3. Cloud Computing
      • 9.3.2.4. Bluetooth
  • 9.4. Market Attractiveness Analysis By Technology

10. Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033, by Usage

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis By Usage, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Usage, 2024-2033
    • 10.3.1. Disposable Injectors
    • 10.3.2. Reusable Injectors
  • 10.4. Market Attractiveness Analysis By Usage

11. Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033, by Indication

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis By Indication, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Indication, 2024-2033
    • 11.3.1. Anaphylaxis
    • 11.3.2. Diabetes
    • 11.3.3. Cardiovascular Diseases
    • 11.3.4. Multiple Sclerosis
    • 11.3.5. Rheumatoid Arthritis
    • 11.3.6. Cancer
    • 11.3.7. Others
  • 11.4. Market Attractiveness Analysis By Indication

12. Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033, by Distribution Channel

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Drug Stores
    • 12.3.3. Retail Pharmacies
    • 12.3.4. Online Pharmacies
  • 12.4. Market Attractiveness Analysis By Distribution Channel

13. Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033, by Region

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 13.3. Current Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. South Asia
    • 13.3.5. East Asia
    • 13.3.6. Oceania
    • 13.3.7. Middle East and Africa
  • 13.4. Market Attractiveness Analysis By Region

14. North America Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. U.S.
      • 14.3.1.2. Canada
    • 14.3.2. By Product
    • 14.3.3. By Technology
    • 14.3.4. By Usage
    • 14.3.5. By Indication
    • 14.3.6. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Technology
    • 14.4.4. By Usage
    • 14.4.5. By Indication
    • 14.4.6. By Distribution Channel
  • 14.5. Country Level Analysis & Forecast
    • 14.5.1. U.S. Injectable Drug Delivery Market
      • 14.5.1.1. Introduction
      • 14.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.1.2.1. By Product
        • 14.5.1.2.2. By Technology
        • 14.5.1.2.3. By Usage
        • 14.5.1.2.4. By Indication
        • 14.5.1.2.5. By Distribution Channel
    • 14.5.2. Canada Injectable Drug Delivery Market
      • 14.5.2.1. Introduction
      • 14.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.5.2.2.1. By Product
        • 14.5.2.2.2. By Technology
        • 14.5.2.2.3. By Usage
        • 14.5.2.2.4. By Indication
        • 14.5.2.2.5. By Distribution Channel
  • 14.6. Drivers and Restraints - Impact Analysis

15. Latin America Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. Brazil
      • 15.3.1.2. Mexico
      • 15.3.1.3. Argentina
      • 15.3.1.4. Rest of Latin America
    • 15.3.2. By Product
    • 15.3.3. By Technology
    • 15.3.4. By Usage
    • 15.3.5. By Indication
    • 15.3.6. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Technology
    • 15.4.4. By Usage
    • 15.4.5. By Indication
    • 15.4.6. By Distribution Channel
  • 15.5. Country Level Analysis & Forecast
    • 15.5.1. Brazil Injectable Drug Delivery Market Analysis
      • 15.5.1.1. Introduction
      • 15.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.1.2.1. By Product
        • 15.5.1.2.2. By Technology
        • 15.5.1.2.3. By Usage
        • 15.5.1.2.4. By Indication
        • 15.5.1.2.5. By Distribution Channel
    • 15.5.2. Mexico Injectable Drug Delivery Market Analysis
      • 15.5.2.1. Introduction
      • 15.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.2.2.1. By Product
        • 15.5.2.2.2. By Technology
        • 15.5.2.2.3. By Usage
        • 15.5.2.2.4. By Indication
        • 15.5.2.2.5. By Distribution Channel
    • 15.5.3. Argentina Injectable Drug Delivery Market Analysis
      • 15.5.3.1. Introduction
      • 15.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.5.3.2.1. By Product
        • 15.5.3.2.2. By Technology
        • 15.5.3.2.3. By Usage
        • 15.5.3.2.4. By Indication
        • 15.5.3.2.5. By Distribution Channel
  • 15.6. Drivers and Restraints - Impact Analysis

16. Europe Global Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Germany
      • 16.3.1.2. Italy
      • 16.3.1.3. France
      • 16.3.1.4. U.K.
      • 16.3.1.5. Spain
      • 16.3.1.6. BENELUX
      • 16.3.1.7. Russia
      • 16.3.1.8. Nordic Countries
      • 16.3.1.9. Rest of Europe
    • 16.3.2. By Product
    • 16.3.3. By Technology
    • 16.3.4. By Usage
    • 16.3.5. By Indication
    • 16.3.6. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Technology
    • 16.4.4. By Usage
    • 16.4.5. By Indication
    • 16.4.6. By Distribution Channel
  • 16.5. Country Level Analysis & Forecast
    • 16.5.1. Germany Injectable Drug Delivery Market
      • 16.5.1.1. Introduction
      • 16.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.1.2.1. By Product
        • 16.5.1.2.2. By Technology
        • 16.5.1.2.3. By Usage
        • 16.5.1.2.4. By Indication
        • 16.5.1.2.5. By Distribution Channel
    • 16.5.2. Italy Injectable Drug Delivery Market
      • 16.5.2.1. Introduction
      • 16.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.2.2.1. By Product
        • 16.5.2.2.2. By Technology
        • 16.5.2.2.3. By Usage
        • 16.5.2.2.4. By Indication
        • 16.5.2.2.5. By Distribution Channel
    • 16.5.3. France Injectable Drug Delivery Market
      • 16.5.3.1. Introduction
      • 16.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.3.2.1. By Product
        • 16.5.3.2.2. By Technology
        • 16.5.3.2.3. By Usage
        • 16.5.3.2.4. By Indication
        • 16.5.3.2.5. By Distribution Channel
    • 16.5.4. U.K. Global Injectable Drug Delivery Market
      • 16.5.4.1. Introduction
      • 16.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.4.2.1. By Product
        • 16.5.4.2.2. By Technology
        • 16.5.4.2.3. By Usage
        • 16.5.4.2.4. By Indication
        • 16.5.4.2.5. By Distribution Channel
    • 16.5.5. Spain Injectable Drug Delivery Market
      • 16.5.5.1. .Introduction
      • 16.5.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.5.2.1. By Product
        • 16.5.5.2.2. By Technology
        • 16.5.5.2.3. By Usage
        • 16.5.5.2.4. By Indication
        • 16.5.5.2.5. By Distribution Channel
    • 16.5.6. BENELUX Injectable Drug Delivery Market
      • 16.5.6.1. .Introduction
      • 16.5.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.6.2.1. By Product
        • 16.5.6.2.2. By Technology
        • 16.5.6.2.3. By Usage
        • 16.5.6.2.4. By Indication
        • 16.5.6.2.5. By Distribution Channel
    • 16.5.7. Russia Injectable Drug Delivery Market
      • 16.5.7.1. .Introduction
      • 16.5.7.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.7.2.1. By Product
        • 16.5.7.2.2. By Technology
        • 16.5.7.2.3. By Usage
        • 16.5.7.2.4. By Indication
        • 16.5.7.2.5. By Distribution Channel
    • 16.5.8. Nordic Countries Injectable Drug Delivery Market
      • 16.5.8.1. .Introduction
      • 16.5.8.2. Market Analysis and Forecast by Market Taxonomy
        • 16.5.8.2.1. By Product
        • 16.5.8.2.2. By Technology
        • 16.5.8.2.3. By Usage
        • 16.5.8.2.4. By Indication
        • 16.5.8.2.5. By Distribution Channel
  • 16.6. Drivers and Restraints - Impact Analysis

17. South Asia Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. India
      • 17.3.1.2. Thailand
      • 17.3.1.3. Indonesia
      • 17.3.1.4. Malaysia
      • 17.3.1.5. Rest of South Asia
    • 17.3.2. By Product
    • 17.3.3. By Technology
    • 17.3.4. By Usage
    • 17.3.5. By Indication
    • 17.3.6. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Technology
    • 17.4.4. By Usage
    • 17.4.5. By Indication
    • 17.4.6. By Distribution Channel
  • 17.5. Country Level Analysis & Forecast
    • 17.5.1. India Injectable Drug Delivery Market Analysis
      • 17.5.1.1. Introduction
      • 17.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.1.2.1. By Product
        • 17.5.1.2.2. By Technology
        • 17.5.1.2.3. By Usage
        • 17.5.1.2.4. By Indication
        • 17.5.1.2.5. By Distribution Channel
    • 17.5.2. Thailand Injectable Drug Delivery Market Analysis
      • 17.5.2.1. .Introduction
      • 17.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.2.2.1. By Product
        • 17.5.2.2.2. By Technology
        • 17.5.2.2.3. By Usage
        • 17.5.2.2.4. By Indication
        • 17.5.2.2.5. By Distribution Channel
    • 17.5.3. Indonesia Injectable Drug Delivery Market Analysis
      • 17.5.3.1. Introduction
      • 17.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.3.2.1. By Product
        • 17.5.3.2.2. By Technology
        • 17.5.3.2.3. By Usage
        • 17.5.3.2.4. By Indication
        • 17.5.3.2.5. By Distribution Channel
    • 17.5.4. Malaysia Injectable Drug Delivery Market Analysis
      • 17.5.4.1. Introduction
      • 17.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.5.4.2.1. By Product
        • 17.5.4.2.2. By Technology
        • 17.5.4.2.3. By Usage
        • 17.5.4.2.4. By Indication
        • 17.5.4.2.5. By Distribution Channel
  • 17.6. Drivers and Restraints - Impact Analysis

18. East Asia Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2024-2033
    • 18.3.1. By Country
      • 18.3.1.1. China
      • 18.3.1.2. Japan
      • 18.3.1.3. South Korea
    • 18.3.2. By Product
    • 18.3.3. By Technology
    • 18.3.4. By Usage
    • 18.3.5. By Indication
    • 18.3.6. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By Technology
    • 18.4.4. By Usage
    • 18.4.5. By Indication
    • 18.4.6. By Distribution Channel
  • 18.5. Country Level Analysis & Forecast
    • 18.5.1. China Injectable Drug Delivery Market Analysis
      • 18.5.1.1. Introduction
      • 18.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.1.2.1. By Product
        • 18.5.1.2.2. By Technology
        • 18.5.1.2.3. By Usage
        • 18.5.1.2.4. By Indication
        • 18.5.1.2.5. By Distribution Channel
    • 18.5.2. Japan Injectable Drug Delivery Market Analysis
      • 18.5.2.1. Introduction
      • 18.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.2.2.1. By Product
        • 18.5.2.2.2. By Technology
        • 18.5.2.2.3. By Usage
        • 18.5.2.2.4. By Indication
        • 18.5.2.2.5. By Distribution Channel
    • 18.5.3. South Korea Injectable Drug Delivery Market Analysis
      • 18.5.3.1. Introduction
      • 18.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.5.3.2.1. By Product
        • 18.5.3.2.2. By Technology
        • 18.5.3.2.3. By Usage
        • 18.5.3.2.4. By Indication
        • 18.5.3.2.5. By Distribution Channel
  • 18.6. Drivers and Restraints - Impact Analysis

19. Oceania Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2024-2033
    • 19.3.1. By Country
      • 19.3.1.1. Australia
      • 19.3.1.2. New Zealand
    • 19.3.2. By Product
    • 19.3.3. By Technology
    • 19.3.4. By Usage
    • 19.3.5. By Indication
    • 19.3.6. By Distribution Channel
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Product
    • 19.4.3. By Technology
    • 19.4.4. By Usage
    • 19.4.5. By Indication
    • 19.4.6. By Distribution Channel
  • 19.5. Country Level Analysis & Forecast
    • 19.5.1. Australia Injectable Drug Delivery Market Analysis
      • 19.5.1.1. Introduction
      • 19.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.5.1.2.1. By Product
        • 19.5.1.2.2. By Technology
        • 19.5.1.2.3. By Usage
        • 19.5.1.2.4. By Indication
        • 19.5.1.2.5. By Distribution Channel
    • 19.5.2. New Zealand Injectable Drug Delivery Market Analysis
      • 19.5.2.1. Introduction
      • 19.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.5.2.2.1. By Product
        • 19.5.2.2.2. By Technology
        • 19.5.2.2.3. By Usage
        • 19.5.2.2.4. By Indication
        • 19.5.2.2.5. By Distribution Channel
  • 19.6. Drivers and Restraints - Impact Analysis

20. Middle East and Africa Injectable Drug Delivery Market Analysis 2019-2023 and Forecast 2024-2033

  • 20.1. Introduction
  • 20.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2019-2023
  • 20.3. Market Size (US$ Bn) Forecast By Market Taxonomy, 2024-2033
    • 20.3.1. By Country
      • 20.3.1.1. GCC Countries
      • 20.3.1.2. Turkey
      • 20.3.1.3. North Africa
      • 20.3.1.4. South Africa
      • 20.3.1.5. Rest of Middle East and Africa
    • 20.3.2. By Product
    • 20.3.3. By Technology
    • 20.3.4. By Usage
    • 20.3.5. By Indication
    • 20.3.6. By Distribution Channel
  • 20.4. Market Attractiveness Analysis
    • 20.4.1. By Country
    • 20.4.2. By Product
    • 20.4.3. By Technology
    • 20.4.4. By Usage
    • 20.4.5. By Indication
    • 20.4.6. By Distribution Channel
  • 20.5. Country Level Analysis & Forecast
    • 20.5.1. GCC Countries Injectable Drug Delivery Market Analysis
      • 20.5.1.1. Introduction
      • 20.5.1.2. Market Analysis and Forecast by Market Taxonomy
        • 20.5.1.2.1. By Product
        • 20.5.1.2.2. By Technology
        • 20.5.1.2.3. By Usage
        • 20.5.1.2.4. By Indication
        • 20.5.1.2.5. By Distribution Channel
    • 20.5.2. Turkey Injectable Drug Delivery Market Analysis
      • 20.5.2.1. Introduction
      • 20.5.2.2. Market Analysis and Forecast by Market Taxonomy
        • 20.5.2.2.1. By Product
        • 20.5.2.2.2. By Technology
        • 20.5.2.2.3. By Usage
        • 20.5.2.2.4. By Indication
        • 20.5.2.2.5. By Distribution Channel
    • 20.5.3. North Africa Injectable Drug Delivery Market Analysis
      • 20.5.3.1. Introduction
      • 20.5.3.2. Market Analysis and Forecast by Market Taxonomy
        • 20.5.3.2.1. By Product
        • 20.5.3.2.2. By Technology
        • 20.5.3.2.3. By Usage
        • 20.5.3.2.4. By Indication
        • 20.5.3.2.5. By Distribution Channel
    • 20.5.4. South Africa Injectable Drug Delivery Market Analysis
      • 20.5.4.1. Introduction
      • 20.5.4.2. Market Analysis and Forecast by Market Taxonomy
        • 20.5.4.2.1. By Product
        • 20.5.4.2.2. By Technology
        • 20.5.4.2.3. By Usage
        • 20.5.4.2.4. By Indication
        • 20.5.4.2.5. By Distribution Channel
  • 20.6. Drivers and Restraints - Impact Analysis

21. Market Structure Analysis

  • 21.1. Market Analysis by Tier of Companies
  • 21.2. Market Share Analysis of Top Players
  • 21.3. Market Presence Analysis

22. Competition Analysis

  • 22.1. Competition Dashboard
  • 22.2. Competition Deep Dive
    • 22.2.1. Eli Lilly and Company
      • 22.2.1.1. Overview
      • 22.2.1.2. Product Portfolio
      • 22.2.1.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.1.4. Sales Footprint
      • 22.2.1.5. Strategy Overview
    • 22.2.2. Biocon
      • 22.2.2.1. Overview
      • 22.2.2.2. Product Portfolio
      • 22.2.2.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.2.4. Sales Footprint
      • 22.2.2.5. Strategy Overview
    • 22.2.3. Becton, Dickinson & Company
      • 22.2.3.1. Overview
      • 22.2.3.2. Product Portfolio
      • 22.2.3.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.3.4. Sales Footprint
      • 22.2.3.5. Strategy Overview
    • 22.2.4. West Pharmaceutical Services, Inc.
      • 22.2.4.1. Overview
      • 22.2.4.2. Product Portfolio
      • 22.2.4.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.4.4. Sales Footprint
      • 22.2.4.5. Strategy Overview
    • 22.2.5. Johnson & Johnson
      • 22.2.5.1. Overview
      • 22.2.5.2. Product Portfolio
      • 22.2.5.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.5.4. Sales Footprint
      • 22.2.5.5. Strategy Overview
    • 22.2.6. Antares Pharma
      • 22.2.6.1. Overview
      • 22.2.6.2. Product Portfolio
      • 22.2.6.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.6.4. Sales Footprint
      • 22.2.6.5. Strategy Overview
    • 22.2.7. AbbVie Inc
      • 22.2.7.1. Overview
      • 22.2.7.2. Product Portfolio
      • 22.2.7.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.7.4. Sales Footprint
      • 22.2.7.5. Strategy Overview
    • 22.2.8. Pfizer Inc.
      • 22.2.8.1. Overview
      • 22.2.8.2. Product Portfolio
      • 22.2.8.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.8.4. Sales Footprint
      • 22.2.8.5. Strategy Overview
    • 22.2.9. Mylan N.V.
      • 22.2.9.1. Overview
      • 22.2.9.2. Product Portfolio
      • 22.2.9.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.9.4. Sales Footprint
      • 22.2.9.5. Strategy Overview
    • 22.2.10. Vetter Pharma-Fertigung GmbH & Co.KG
      • 22.2.10.1. Overview
      • 22.2.10.2. Product Portfolio
      • 22.2.10.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.10.4. Sales Footprint
      • 22.2.10.5. Strategy Overview
    • 22.2.11. Emperra GmbH
      • 22.2.11.1. Overview
      • 22.2.11.2. Product Portfolio
      • 22.2.11.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.11.4. Sales Footprint
      • 22.2.11.5. Strategy Overview
    • 22.2.12. Digital Medics Pty Ltd
      • 22.2.12.1. Overview
      • 22.2.12.2. Product Portfolio
      • 22.2.12.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.12.4. Sales Footprint
      • 22.2.12.5. Strategy Overview
    • 22.2.13. Enable Injections LLC
      • 22.2.13.1. Overview
      • 22.2.13.2. Product Portfolio
      • 22.2.13.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.13.4. Sales Footprint
      • 22.2.13.5. Strategy Overview
    • 22.2.14. Insulet corporation
      • 22.2.14.1. Overview
      • 22.2.14.2. Product Portfolio
      • 22.2.14.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.14.4. Sales Footprint
      • 22.2.14.5. Strategy Overview
    • 22.2.15. Consort Medical Plc
      • 22.2.15.1. Overview
      • 22.2.15.2. Product Portfolio
      • 22.2.15.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.15.4. Sales Footprint
      • 22.2.15.5. Strategy Overview
    • 22.2.16. Diabnext
      • 22.2.16.1. Overview
      • 22.2.16.2. Product Portfolio
      • 22.2.16.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.16.4. Sales Footprint
      • 22.2.16.5. Strategy Overview
    • 22.2.17. Diamesco Co., Ltd
      • 22.2.17.1. Overview
      • 22.2.17.2. Product Portfolio
      • 22.2.17.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.17.4. Sales Footprint
      • 22.2.17.5. Strategy Overview
    • 22.2.18. SCHOTT AG
      • 22.2.18.1. Overview
      • 22.2.18.2. Product Portfolio
      • 22.2.18.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.18.4. Sales Footprint
      • 22.2.18.5. Strategy Overview
    • 22.2.19. SiO2 Medical Products
      • 22.2.19.1. Overview
      • 22.2.19.2. Product Portfolio
      • 22.2.19.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.19.4. Sales Footprint
      • 22.2.19.5. Strategy Overview
    • 22.2.20. Integrity Bio, Inc.
      • 22.2.20.1. Overview
      • 22.2.20.2. Product Portfolio
      • 22.2.20.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.20.4. Sales Footprint
      • 22.2.20.5. Strategy Overview
    • 22.2.21. Wilhelm Haselmeier GmbH & Co. KG
      • 22.2.21.1. Overview
      • 22.2.21.2. Product Portfolio
      • 22.2.21.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.21.4. Sales Footprint
      • 22.2.21.5. Strategy Overview
    • 22.2.22. Tandem Diabetes Care
      • 22.2.22.1. Overview
      • 22.2.22.2. Product Portfolio
      • 22.2.22.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.22.4. Sales Footprint
      • 22.2.22.5. Strategy Overview
    • 22.2.23. Sanofi S.A.
      • 22.2.23.1. Overview
      • 22.2.23.2. Product Portfolio
      • 22.2.23.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.23.4. Sales Footprint
      • 22.2.23.5. Strategy Overview
    • 22.2.24. Companion Medical Inc.
      • 22.2.24.1. Overview
      • 22.2.24.2. Product Portfolio
      • 22.2.24.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.24.4. Sales Footprint
      • 22.2.24.5. Strategy Overview
    • 22.2.25. Ypsomed
      • 22.2.25.1. Overview
      • 22.2.25.2. Product Portfolio
      • 22.2.25.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.25.4. Sales Footprint
      • 22.2.25.5. Strategy Overview
    • 22.2.26. F.Hoffman - La Roche Ltd.
      • 22.2.26.1. Overview
      • 22.2.26.2. Product Portfolio
      • 22.2.26.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.26.4. Sales Footprint
      • 22.2.26.5. Strategy Overview
    • 22.2.27. Novo Nordisk A/S
      • 22.2.27.1. Overview
      • 22.2.27.2. Product Portfolio
      • 22.2.27.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.27.4. Sales Footprint
      • 22.2.27.5. Strategy Overview
    • 22.2.28. Medtronic Plc.
      • 22.2.28.1. Overview
      • 22.2.28.2. Product Portfolio
      • 22.2.28.3. Profitability by Market Segments (Product/Channel/Region)
      • 22.2.28.4. Sales Footprint
      • 22.2.28.5. Strategy Overview

23. Assumptions and Acronyms Used

24. Research Methodology